those appearing in every-day practice, it is essential to individualize treatment options taking into account the results of clinical trials.
INTRODUCTION
According to recent epidemiological data, 2.3% of the population aged over 65 years in Europe is suffering from neovascular (wet) age-related macular degeneration (wAMD), with the disease posing a significant public health problem [1] [2] [3] . wAMD is diagnosed less often than dry AMD, yet it accounts for 90% of severe vision loss cases [1, 2] .
During the past decade, new targeted treatments against vascular endothelial growth factor (anti-VEGF agents) have been introduced in the management of wAMD patients changing the visual prognosis in these patients [4] . A large benefit in vision of patients treated with ranibizumab was initially highlighted in large multicenter trials, followed by the use of bevacizumab and recently aflibercept [5] [6] [7] [8] [9] .
Moreover, diagnostic technologies, and especially optical coherence tomography (OCT) have revolutionized the AMD diagnosis and treatment algorithm [10] . However, despite positive developments in disease management, there are no commonly accepted therapeutic response evaluation criteria. This is particularly true when the discussion is not limited to patients that are selected based on criteria similar to those in large clinical trials, but when referring to the individual patient, treated by an ophthalmologist in everyday clinical practice. In addition, there is ongoing research for parameters predictive or suggestive of no response to anti-VEGF therapy since the characteristics of patients not responding to treatment are not clearly defined. Thus, deriving the maximum possible benefit for each individual patient in the clinic becomes more difficult.
The purpose of this article is to present guidelines, compiled by a panel of specialized ophthalmologists in the area of wAMD, and propose commonly accepted therapeutic response criteria and define treatment discontinuation criteria for patients suffering from wAMD treated with anti-VEGF agents. 
INITIAL EVALUATION
Prior to treatment initiation, compliance with the examination algorithm depicted in Fig. 1 Techniques, such as angiography and autofluorescence are particularly important in special circumstances (Table 3) 
THERAPEUTIC RESPONSE DEFINITION BASED ON ANATOMIC PARAMETERS
Response to treatment is evaluated based on anatomic and functional criteria. Anatomic criteria can provide qualitative and quantitative information. Based on anatomic • Reduction in CRT compared to baseline. CRT ranging between 250-350 lm is generally considered satisfactory.
• Partial or complete resolution of subretinal fluid.
• Reduction in subretinal fluid versus baseline.
• Reduction in PED extent and height.
• Restoration of the outer retinal layers anatomy.
Observations
• Lack of relapses constitutes an additional efficacy criterion. The time free of disease activity should be taken into account when evaluating the effect of treatment.
• Re-treatment criteria include non-stabilization and fluctuation of visual acuity (continuing improvement or gradual deterioration), as well as anatomic deterioration (e.g., retinal thickness increase by 100 lm, PED or increase in SRF).
• In the case of bilateral disease, concomitant and independent treatment administration is recommended for both eyes [31] .
NON-RESPONSE TO TREATMENT WITH ANTI-ANGIOGENIC FACTORS IN WAMD
It is a recognized fact that not all patients Therefore, anatomic signs of ongoing wAMD activity should in fact be carefully taken into account to support non-response to anti-VEGF therapy.
Functional Parameters
• Vision loss of more than 10 ETDRS letters (or 2 Snellen lines). 
Anatomic Parameters
• Edema increase (CRT increase [100 lm).
• Increase in SRF.
• anti-VEGF therapy. Therefore, it should be emphasized that the decision of non-response to treatment may only be made when the strict protocol of 4-weekly treatment intervals has been followed.
In this case, a re-evaluation should be performed using FA/ICGA or any other method considered appropriate by the treating physician to rule out other entities.
If the diagnosis of choroidal neovascularization due to wAMD is confirmed then:
• The treatment should be continued on a monthly basis, for up to a total of 6 months. The algorithm in Fig. 2 shows patient follow-up upon suspicion of non-response or development of factors able to negatively affect response.
TREATMENT DISCONTINUATION CRITERIA
In the case of a patient that fulfills the below-mentioned criteria, (s)he is characterized as non-responder and may discontinue anti-angiogenetic factor treatment:
• Visual acuity decline at a level less than 1/20 in three sequential visits, due to wAMD.
• Lesion morphology deterioration, suggesting ongoing activity, despite appropriate treatment (e.g., progressive increase in the size of the lesion confirmed with fluorescein angiography, features on OCT suggesting disease activity or new hemorrhages or exudates (not related to vascular disease), providing evidence of ongoing activity). Additionally, knowledge around genetic factors that appear to be important factors controlling response to anti-VEGF treatment is also emerging. Interestingly, low-risk complement factor H phenotypes may in fact predict a favorable response compared to the high-risk group [53] . It remains, however, unknown how this increasing knowledge can translate in clinical practice and whether it will change our treatment approach. Finally, progression of atrophy should be carefully observed during prolonged treatment, since it represents an important factor in determining visual outcome [54] .
GUIDANCE FOR PATIENTS THAT ALREADY SUSTAINED PROFOUND VISION LOSS IN THE OTHER EYE
Given the chronic nature of the disease, future studies may further highlight factors that are important for the long-term visual prognosis of the individual wAMD patient. 
